<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Aspirantskiy Vestnik Povolzhiya</journal-id><journal-title-group><journal-title xml:lang="en">Aspirantskiy Vestnik Povolzhiya</journal-title><trans-title-group xml:lang="ru"><trans-title>Аспирантский вестник Поволжья</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-2354</issn><issn publication-format="electronic">2410-3764</issn><publisher><publisher-name xml:lang="en">Samara State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">689440</article-id><article-id pub-id-type="doi">10.35693/AVP689440</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>UROLOGY AND ANDROLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>УРОЛОГИЯ И АНДРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Predictors of common survival in patients with testicular cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Предикторы общей выживаемости у пациентов с раком яичка</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4998-3779</contrib-id><name-alternatives><name xml:lang="en"><surname>Isargapov</surname><given-names>Ruslan M.</given-names></name><name xml:lang="ru"><surname>Исаргапов</surname><given-names>Руслан Маликович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), oncologist, assistant of the Department of Oncology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, врач-онколог, ассистент кафедры онкологии</p></bio><email>ruslan.isargapov@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4569-1031</contrib-id><name-alternatives><name xml:lang="en"><surname>Kaganov</surname><given-names>Oleg I.</given-names></name><name xml:lang="ru"><surname>Каганов</surname><given-names>О. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Head of the Department of Oncology, Chief Physician</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующий кафедрой онкологии, главный врач</p></bio><email>o.i.kaganov@samsmu.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5385-7049</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>Ramilya D.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Р. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, assistant of the Department of Urology</p></bio><bio xml:lang="ru"><p>ассистент кафедры урологии</p></bio><email>r.d.andreeva@samsmu.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4452-8547</contrib-id><name-alternatives><name xml:lang="en"><surname>Nizamova</surname><given-names>Rumiya S.</given-names></name><name xml:lang="ru"><surname>Низамова</surname><given-names>Р. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Head of the Department of Urology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой урологии</p></bio><email>r.s.nizamova@samsmu.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-8280-3445</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozova</surname><given-names>Ekaterina E.</given-names></name><name xml:lang="ru"><surname>Морозова</surname><given-names>Е. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5th year student</p></bio><bio xml:lang="ru"><p>студентка 5 курса</p></bio><email>katya.morozova-k@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Samara State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution></aff><aff><institution xml:lang="kk"></institution></aff><aff><institution xml:lang="pt"></institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Samara Regional Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Самарский областной клинический онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Samara State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-11-12" publication-format="electronic"><day>12</day><month>11</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-09" publication-format="electronic"><day>09</day><month>12</month><year>2025</year></pub-date><volume>25</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>53</fpage><lpage>59</lpage><history><date date-type="received" iso-8601-date="2025-08-18"><day>18</day><month>08</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-20"><day>20</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Isargapov R.M., Kaganov O.I., Andreeva R.D., Nizamova R.S., Morozova E.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Исаргапов Р.М., Каганов О.И., Андреева Р.Д., Низамова Р.С., Морозова Е.Е.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Isargapov R.M., Kaganov O.I., Andreeva R.D., Nizamova R.S., Morozova E.E.</copyright-holder><copyright-holder xml:lang="ru">Исаргапов Р.М., Каганов О.И., Андреева Р.Д., Низамова Р.С., Морозова Е.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://aspvestnik.ru/2410-3764/article/view/689440">https://aspvestnik.ru/2410-3764/article/view/689440</self-uri><abstract xml:lang="en"><p><bold>Aim</bold> – to study own experience of treating patients with testicular cancer, to assess the overall survival rates, as well as the risk factors affecting it.</p> <p><bold>Material and methods.</bold> The study included 221 patients with a newly diagnosed testicular cancer in 2007–2022. All patients underwent orchifuniculectomy with subsequent chemotherapy. Kaplan – Meier survival curves were constructed to assess the time to death from any cause and to compare factors affecting mortality.</p> <p><bold>Results. </bold>The 10-year overall survival rate was 83%. Patients with left-sided tumor localization had a poorer prognosis (p&lt;0.05). The 10-year overall survival rate was 89% for right-sided localization and 79% for left-sided localization. Stages T2 and T3 significantly worsened the overall survival prognosis. The 10-year overall survival rate was 92% for T1, 85% for T2, and 68% for T3.</p> <p>Survival rates were higher in the N0 and N1 groups than in the N1 and N2 groups (p&lt;0.05). The 10-year overall survival rate was 100% for N0, 93% for N1, 60% for N2, and 49% for N3. Patients with M1 stage had a worse prognosis for overall survival (p &lt;0.05). The 10-year overall survival rate in rural residents (91%) was statistically significantly different from the survival rate in urban residents (82%) p &lt;0.05. The overall survival rate in younger patients was 97%, while in men over 40 years of age it was 86% (p&lt;0.05).</p> <p><bold>Conclusions.</bold> The stage of the disease, place of residence, age, and side of the lesion are statistically significant predictors of survival in patients with testicular cancer.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold> – изучить собственный опыт лечения пациентов с раком яичка, оценить показатели общей выживаемости, а также влияющие на нее факторы риска.</p> <p><bold>Материал и методы. </bold>В исследование вошел 221 пациент с впервые установленным диагнозом «рак яичка» за период 2007–2022 гг. Всем пациентам проведена орхфуникулэктомия с последующей химиотерапией. Для оценки времени до наступления неблагоприятного исхода (смерти от любой причины), а также для сопоставления факторов, влияющих на смертность, строили кривые дожития Каплана – Мейера.</p> <p><bold>Результаты.</bold> Показатель 10-летней общей выживаемости составил 83%. Худший прогноз имели пациенты с левосторонней локализацией опухоли (p&lt;0,05). Показатель 10-летней общей выживаемости при правосторонней локализации составил 89%, при поражении слева – 79%. Стадии T2 и T3 статистически значимо ухудшали прогноз общей выживаемости. Показатель 10-летней общей выживаемости при стадии T1 составил 92%, при Т2 – 85% и при T3 – 68%. Показатели выживаемости выше в группе пациентов со стадией N0 и N1, чем в группах N1 и N2 (p&lt;0,05). Показатель 10-летней общей выживаемости при N0 – 100%, при N1 – 93%, при N2 – 60%, при N3 – 49%. Пациенты со стадией M1 при оценке общей выживаемости имели худший прогноз (p &lt;0,05). Показатель 10-летней общей выживаемости у жителей сельской местности (91%) статистически значимо отличался от выживаемости жителей города (82%) p&lt;0,05. Общая выживаемость у более молодых пациентов составила 97%, у мужчин старше 40 лет – 86% (p&lt;0,05).</p> <p><bold>Выводы. </bold>Стадия заболевания, место жительства, возраст, а также сторона поражения являются статистически значимыми предикторами выживаемости у больных раком яичка.</p></trans-abstract><kwd-group xml:lang="en"><kwd>testicular cancer</kwd><kwd>survival predictors</kwd><kwd>overall survival</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак яичка</kwd><kwd>предикторы выживаемости</kwd><kwd>общая выживаемость</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>De Padua Mansur A, Favarato D. Cardiovascular and Cancer Death Rates in the Brazilian Population Aged 35 to 74 Years, 1996–2017. Arq Bras Cardiol. 2021;117:329-340. DOI: 10.36660/abc.20200233</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Prades S, Jos SL, Saïas-Magnan J, et al. Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data. Basic Clin Androl. 2023;33:35. DOI: 10.1186/s12610-023-00209-8</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297-1305. DOI: https://doi.org/10.1016/j.eururo.2008.02.039</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dimitropoulos K, Karatzas A, Papandreou C, et al. Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: A focus beyond ejaculation disorders. Andrologia. 2016;48:425-430. DOI: 10.1111/and.12462</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Koyama J, Yamashita S, Yamada S, et al. Impact of cancer therapy on post-treatment ejaculation disorder and sexual life in testicular cancer survivors. Int J Urol. 2021;28:69-74. DOI: 10.1111/iju.14403</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>van Basten JP, van Driel MF, Jonker-Pool G, et al. Sexual functioning in testosterone-supplemented patients treated for bilateral testicular cancer. Br J Urol. 1997;79:461-467 DOI: 10.1046/j.1464-410x.1997.00027.x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Yazici S, Del Biondo D, Napodano G, et al. Risk factors for testicular cancer: environment, genes and infections - is it all? Medicina (Kaunas). 2023;59(4):724. DOI: 10.3390/medicina59040724</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2019 (incidence and mortality). M., 2023. (In Russ.). [Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2019 г. (заболеваемость и смертность). М., 2023].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine. 2018;97:e12390. DOI: 10.1097/MD.0000000000012390</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>van Basten JP, Jonker-Pool G, van Driel MF, et al. Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. J Urol. 1997;158:1411-1416. DOI: 10.1097/00005392-199710000-00024</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Purdue MP, Devesa SS, Sigurdson AJ, et al. International patterns and trends in testis cancer incidence. Int J Cancer. 2005;115:822-827. DOI: 10.1002/ijc.20931</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bray F, Ferlay J, Devesa SS, et al. Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol. 2006;3:532-543. DOI: 10.1038/ncpuro0606</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chong RIH, Leow JJ, Choo ZW, et al. Testicular self-examination for early detection of testicular cancer. World J Urol. 2023;41:941-951. DOI: 10.1007/s00345-023-04381-4</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Maiolino G, Fernández-Pascual E, Ochoa Arvizo MA, et al. Male Infertility and the Risk of Developing Testicular Cancer: A Critical Contemporary Literature Review. Medicina (Kaunas). 2023;59:1305. DOI: 10.3390/medicina59071305</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Funt SA, Feldman DR, Bosl GJ. The management of advanced germ cell tumors in 2016: the memorial Sloan Kettering approach. Oncology (Williston Park). 2016;30:653-664. PMID: 27422113</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054-68. DOI: 10.1016/j.eururo.2015.07.044</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dahl AA, Bremnes R, Dahl O, et al. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol. 2007;52:1438-47. DOI: 10.1016/j.eururo.2007.02.046</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gospodarowicz MK, Brierley JD, Wittekind C, et al. TNM classification of malignant tumors 8th ed. Wiley-Blackwell. 2017: 262-265. URL: http://mom.gov.az/resources/content_files/ebook/TNM-Classification-of-Malignant-Tumours-8th-edition.pdf</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ustinova TV, Bolotina LV, Fedenko AA, et al. Combined treatment of a patient with a testicular germ cell tumor with signs of multiple organ failure. Research and Practical Medicine Journal. 2019;6(3):129-137. [Устинова Т.В., Болотина Л.В., Феденко А.А., и др. Комбинированное лечение пациента с герминогенной опухолью яичка с признаками полиорганной недостаточности. Research and Practical Medicine Journal. 2019;6(3):129-137]. DOI: 10.17709/2409-2231-2019-6-3-12</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Nemtsova MV, Andreeva YuYu. Testicular germ cell tumors: Molecular genetic and clinicomorphological aspects. Cancer Uro-logy. 2015;11(1):12-19. [Немцова М.В., Андреева Ю.Ю. Молекулярно-генетические и клинико-морфологические аспекты герминогенных опухолей яичка. Онкоурология. 2015;11(1):12-19]. DOI: 10.17650/1726-9776-2015-1-12-19</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Biemer J, Pambuccian SE, Barkan GA. Fine needle aspiration diagnosis of metastatic Leydig cell tumor. Report of a case and review of the literature. J Am Soc Cytopathol. 2019;8(4):220-229. DOI: 10.1016/j.jasc.2019.02.001</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Thorup J, McLachlan R, Cortes D, et al. What is new in cryptorchidism and hypospadias-a critical review on the testicular dysgenesis hypothesis. Journal of pediatric surgery. 2010;45(10):2074-86. DOI: 10.1016/j.jpedsurg.2010.07.030</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Clasen SC, Fung C, Sesso HD, Travis LB. Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment. Curr Oncol Rep. 2023;25(5):445-454. DOI: 10.1007/s11912-023-01375-8</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021;39(14):1563-74. DOI: 10.1200/JCO.20.03296</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Rovito MJ, Taylor S, Lockwood R, et al. Testicular Cancer Incidence and Mortality Within Rural and Urban Regions. J Adolesc Young Adult Oncol. 2020;9(2):202-207. DOI: 10.1089/jayao.2019.0102</mixed-citation></ref></ref-list></back></article>
